Missing anemia benefit from "Zerenex" label makes Keryx's phosphate binder a tough sell.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Merck will sell the skin cancer drug under the brand name Keytruda.
Under the agreement, Calico and Abbvie will work together to discover and develop new drugs for age-related diseases, including neuro-degeneration and cancer.
With Ampion failure, Ampio's pipeline is worthless.
Infinity and Abbvie will jointly develop and market duvelisib.
Results from Sunesis' phase III study in acute myeloid leukemia should be released this month or next.
As a result of the negative prostate cancer study, Exelixis intends to downsize by firing 70% of its workforce.
The biotech sector hews close to an academic calendar and September marks the start of the busy, event-filled push into the end of the year.
The iShares Nasdaq Biotechnology ETF closed at 272.63 Monday, less than one point below the year (and all-time) closing high reached on Feb. 25.